Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

GF58573648

Lutetium

powder, 1g, max. particle size 500 micron, 99.9%

Synonym(s):

Lutetium, LU006010

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
Lu
CAS Number:
7439-94-3
Molecular Weight:
174.97
MDL number:
MFCD00011098
UNSPSC Code:
11101711
PubChem Substance ID:
329808836
NACRES:
NA.23

Assay

99.9%

form

powder

manufacturer/tradename

Goodfellow 585-736-48

resistivity

54 μΩ-cm, 20°C

particle size

500 μm

bp

3402 °C (lit.)

mp

1663 °C (lit.)

density

9.84 g/mL at 25 °C (lit.)

SMILES string

[Lu]

InChI

1S/Lu

InChI key

OHSVLFRHMCKCQY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Pictograms

Flame
GHS02

Signal Word

Danger

Hazard Statements

H228

Hazard Classifications

Flam. Sol. 1

Storage Class Code

4.1B - Flammable solid hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R O Perez et al.
Techniques in coloproctology, 18(8), 699-708 (2014-02-11)
Molecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant
B L R Kam et al.
European journal of nuclear medicine and molecular imaging, 39 Suppl 1, S103-S112 (2012-03-06)
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The
S Panigone et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 50(4), 310-321 (2006-10-18)
Optimization of therapy for individual patients remains a goal of clinical practice. Radionuclide imaging can identify those patients who may benefit from subsequent targeted therapy by providing regional information on the distribution of the target. An ideal situation may be
Constantin Lapa et al.
Nuclear medicine and biology, 42(4), 349-354 (2015-01-18)
Peptide receptor radionuclide therapy (PRRT) is a treatment option for both iodine-refractory differentiated and advanced medullary thyroid cancer (TC). It requires over-expression of somatostatin receptor subtype II (SSTR) that can be non-invasively assessed by positron emission tomography (PET). Assessment of
Constantin Lapa et al.
Annals of medicine, 47(7), 538-545 (2015-10-30)
Brown adipose tissue (BAT) attracts growing interest as a potential therapeutic target for obesity and diabetes. Hyperthyroidism is well-known to increase BAT activity, but the role of hypothyroidism is controversial. We aimed to investigate the association between different thyroid hormone
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service